2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Balazs Halmos, MD, MS, discusses the emergence of KRAS-targeted therapies in lung cancer.
Balazs Halmos, MD, MS, director of the Multidisciplinary Thoracic Oncology Program and director of the Section of Thoracic Medical Oncology for Montefiore Health Systems, first director of Clinical Cancer Genetics and professor of clinical medicine at the Albert Einstein College of Medicine, discusses the emergence of KRAS-targeted therapies in lung cancer.
Targeting KRAS mutations in lung cancer is an unfolding story, says Halmos. Efficacy data with KRAS inhibitors as single agents and in combination regimens with conventional first- and second-line options, such as chemotherapy and immunotherapy, will likely emerge in 2021, Halmos explains.
Additionally, as KRAS mutations are present in a significant proportion of patients with lung cancer, the field is hoping to develop an understanding of which investigational KRAS-directed therapy yields the most significant efficacy and in which specific patient populations, concludes Halmos.